Top

Published in:

Open Access 01-12-2022 | SARS-CoV-2 | Research

Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients

Authors: M. Cardelli, E. Pierpaoli, F. Marchegiani, F. Marcheselli, F. Piacenza, R. Giacconi, R. Recchioni, T. Casoli, P. Stripoli, M. Provinciali, G. Matacchione, A. Giuliani, D. Ramini, J. Sabbatinelli, M. Bonafè, M. Di Rosa, A. Cherubini, C. Di Pentima, F. Spannella, R. Antonicelli, A. R. Bonfigli, F. Olivieri, F. Lattanzio

Published in: Immunity & Ageing | Issue 1/2022

Abstract

Background

The risk for symptomatic COVID-19 requiring hospitalization is higher in the older population. The course of the disease in hospitalised older patients may show significant variation, from mild to severe illness, ultimately leading to death in the most critical cases. The analysis of circulating biomolecules involved in mechanisms of inflammation, cell damage and innate immunity could lead to identify new biomarkers of COVID-19 severity, aimed to improve the clinical management of subjects at higher risk of severe outcomes.

In a cohort of COVID-19 geriatric patients (n= 156) who required hospitalization we analysed, on-admission, a series of circulating biomarkers related to neutrophil activation (neutrophil elastase, LL-37), macrophage activation (sCD163) and cell damage (nuclear cfDNA, mithocondrial cfDNA and nuclear cfDNA integrity). The above reported biomarkers were tested for their association with in-hospital mortality and with clinical, inflammatory and routine hematological parameters. Aim of the study was to unravel prognostic parameters for risk stratification of COVID-19 patients.

Results

Lower n-cfDNA integrity, higher neutrophil elastase and higher sCD163 levels were significantly associated with an increased risk of in-hospital decease. Median (IQR) values observed in discharged vs. deceased patients were: 0.50 (0.30-0.72) vs. 0.33 (0.22-0.62) for n-cfDNA integrity; 94.0 (47.7-154.0) ng/ml vs. 115.7 (84.2-212.7) ng/ml for neutrophil elastase; 614.0 (370.0-821.0) ng/ml vs. 787.0 (560.0-1304.0) ng/ml for sCD163. The analysis of survival curves in patients stratified for tertiles of each biomarker showed that patients with n-cfDNA integrity < 0.32 or sCD163 in the range 492-811 ng/ml had higher risk of in-hospital decease than, respectively, patients with higher n-cfDNA integrity or lower sCD163. These associations were further confirmed in multivariate models adjusted for age, sex and outcome-related clinical variables. In these models also high levels of neutrophil elastase (>150 ng/ml) appeared to be independent predictor of in-hospital death. An additional analysis of neutrophil elastase in patients stratified for n-cfDNA integrity levels was conducted to better describe the association of the studied parameters with the outcome.

Conclusions

On the whole, biomarkers of cell-free DNA integrity, neutrophil and macrophage activation might provide a valuable contribution to identify geriatric patients with high risk of COVID-19 in-hospital mortality.

Available only for authorised users

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed 25/03/2022.

Prendki V, Tiseo G, Falcone M. ESCMID Study Group for Infections in the Elderly (ESGIE). Caring for older adults during the COVID-19 pandemic. Clin Microbiol Infect. 2022;28(6):785–91. https://doi.org/10.1016/j.cmi.2022.02.040.CrossRef

Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992–1000.e3. https://doi.org/10.1016/j.chom.2020.04.009.CrossRef

Ombrello MJ, Schulert GS. COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome? Transl Res. 2021;232:1–12. https://doi.org/10.1016/j.trsl.2021.03.002.CrossRef

Sabbatinelli J, Matacchione G, Giuliani A, Ramini D, Rippo MR, Procopio AD, et al. Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes. Mech Ageing Dev. 2022;204:111667. https://doi.org/10.1016/j.mad.2022.111667.CrossRef

Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, et al. Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. Front Immunol. 2021;12:627548. https://doi.org/10.3389/fimmu.2021.627548.CrossRef

Sánchez-Torres C, Gómez-Puertas P, Gómez-del-Moral M, Alonso F, Escribano JM, Ezquerra A, et al. Expression of porcine CD163 on monocytes/macrophages correlates with permissiveness to African swine fever infection. Arch Virol. 2003;148:2307–23.CrossRef

Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197–223.CrossRef

Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2007;5(8):577–82.CrossRef

10.

Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H, et al. Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury. PLoS Pathog. 2015;11(3):e1004651. https://doi.org/10.1371/journal.ppat.1004651.CrossRef

11.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.CrossRef

12.

Szturmowicz M, Demkow U. Neutrophil Extracellular Traps (NETs) in Severe SARS-CoV-2 Lung Disease. Int J Mol Sci. 2021;22(16):8854. https://doi.org/10.3390/ijms22168854.CrossRef

13.

Iliadi V, Konstantinidou I, Aftzoglou K, Iliadis S, Konstantinidis TG, Tsigalou C. The Emerging Role of Neutrophils in the Pathogenesis of Thrombosis in COVID-19. Int J Mol Sci. 2021;22(10):5368. https://doi.org/10.3390/ijms22105368.CrossRef

14.

Block H, Zarbock A. A Fragile Balance: Does Neutrophil Extracellular Trap Formation Drive Pulmonary Disease Progression? Cells. 2021;10(8):1932. https://doi.org/10.3390/cells10081932.CrossRef

15.

Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew AA, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011;179:199–210.CrossRef

16.

Ashar HK, Mueller NC, Rudd JM, Snider TA, Achanta M, Prasanthi M, et al. The Role of Extracellular Histones in Influenza Virus Pathogenesis. Am J Pathol. 2018;188(1):135–48. https://doi.org/10.1016/j.ajpath.2017.09.014.CrossRef

17.

Cahilog Z, Zhao H, Wu L, Alam A, Eguchi S, Weng H, et al. The Role of Neutrophil NETosis in Organ Injury: Novel Inflammatory Cell Death Mechanisms. Inflammation. 2020;43(6):2021–32. https://doi.org/10.1007/s10753-020-01294-x.CrossRef

18.

Grayson PC, Kaplan MJ. At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol. 2016;99(2):253–64. https://doi.org/10.1189/jlb.5BT0615-247R.CrossRef

19.

Moorthy AN, Tan KB, Wang S, Narasaraju T, Chow VT. Effect of high-fat diet on the formation of pulmonary neutrophil extracellular traps during influenza pneumonia in BALB/c mice. Front Immunol. 2016;7:289.CrossRef

20.

Rudd JM, Pulavendran S, Ashar HK, Ritchey JW, Snider TA, Malayer JR, et al. Neutrophils Induce a Novel Chemokine Receptors Repertoire During Influenza Pneumonia. Front Cell Infect Microbiol. 2019;9:108. https://doi.org/10.3389/fcimb.2019.00108.CrossRef

21.

Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther. 2019;20(8):1057–67. https://doi.org/10.1080/15384047.2019.1598759.CrossRef

22.

Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018;4(4):FSO295. https://doi.org/10.4155/fsoa-2017-0140.CrossRef

23.

Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. https://doi.org/10.1084/jem.20200652.CrossRef

24.

Thierry AR, Roch B. Neutrophil Extracellular Traps and By-Products Play a Key Role in COVID-19: Pathogenesis, Risk Factors, and Therapy. J Clin Med. 2020;9(9):2942. https://doi.org/10.3390/jcm9092942.CrossRef

25.

Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. https://doi.org/10.1172/jci.insight.138999.CrossRef

26.

Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062–9. https://doi.org/10.1373/clinchem.2006.068577.CrossRef

27.

Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, et al. Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med (N Y). 2021;2(4):411–422.e5. https://doi.org/10.1016/j.medj.2021.01.001.CrossRef

28.

Storci G, Bonifazi F, Garagnani P, Olivieri F, Bonafè M. The role of extracellular DNA in COVID-19: clues from inflamm-aging. Ageing Res Rev. 2021;66:101234. https://doi.org/10.1016/j.arr.2020.101234.CrossRef

29.

Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112(11):E1317–25. https://doi.org/10.1073/pnas.1500076112.CrossRef

30.

Han DSC, Lo YMD. The Nexus of cfDNA and Nuclease Biology. Trends Genet. 2021;37(8):758–70. https://doi.org/10.1016/j.tig.2021.04.005.CrossRef

31.

Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231–41. https://doi.org/10.1083/jcb.200606027.CrossRef

32.

André S, Picard M, Cezar R, Roux-Dalvai F, Alleaume-Butaux A, Soundaramourty C, et al. T cell apoptosis characterizes severe Covid-19 disease. Cell Death Differ. 2022;29(8):1486–99. https://doi.org/10.1038/s41418-022-00936-x.CrossRef

33.

Parzy E, Bouchaud V, Massot P, Voisin P, Koonjoo N, Moncelet D, et al. Overhauser-enhanced MRI of elastase activity from in vitro human neutrophil degranulation. PLoS One. 2013;8(2):e57946. https://doi.org/10.1371/journal.pone.0057946.CrossRef

34.

Ng H, Havervall S, Rosell A, Aguilera K, Parv K, von Meijenfeldt FA, et al. Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. Arterioscler Thromb Vasc Biol. 2021;41(2):988–94. https://doi.org/10.1161/ATVBAHA.120.315267.CrossRef

35.

Donkel SJ, Wolters FJ, Ikram MA, de Maat MPM. Circulating Myeloperoxidase (MPO)-DNA complexes as marker for Neutrophil Extracellular Traps (NETs) levels and the association with cardiovascular risk factors in the general population. PLoS One. 2021;16(8):e0253698. https://doi.org/10.1371/journal.pone.0253698.CrossRef

36.

Miki S, Sasaki H, Horiuchi H, Miyata N, Yoshimura Y, Miyazaki K, et al. On-admission SARS-CoV-2 RNAemia as a single potent predictive marker of critical condition development and mortality in COVID-19. PLoS One. 2021;16(7):e0254640. https://doi.org/10.1371/journal.pone.0254640.CrossRef

37.

Contoli M, Papi A, Tomassetti L, Rizzo P, Vieceli Dalla Sega F, Fortini F, et al. Blood Interferon-α Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19 Patients. Front Immunol. 2021;12:648004. https://doi.org/10.3389/fimmu.2021.648004.CrossRef

38.

Hammad R, Eldosoky MAER, Fouad SH, Elgendy A, Tawfeik AM, Alboraie M, et al. Circulating cell-free DNA, peripheral lymphocyte subsets alterations and neutrophil lymphocyte ratio in assessment of COVID-19 severity. Innate Immun. 2021;27(3):240–50. https://doi.org/10.1177/1753425921995577.CrossRef

39.

Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev. 2020;53:33–7. https://doi.org/10.1016/j.cytogfr.2020.04.005.CrossRef

40.

Smith P, Rosell A, Farm M, Bruzelius M, Aguilera Gatica K, Mackman N, et al. Markers of neutrophil activation and neutrophil extracellular traps in diagnosing patients with acute venous thromboembolism: A feasibility study based on two VTE cohorts. PLoS One. 2022;17(7):e0270865. https://doi.org/10.1371/journal.pone.0270865.CrossRef

41.

Daftarian N, Zandi S, Piryaie G, Nikougoftar Zarif M, Ranaei Pirmardan E, Yamaguchi M, et al. Peripheral blood CD163(+) monocytes and soluble CD163 in dry and neovascular age-related macular degeneration. FASEB J. 2020;34(6):8001–11. https://doi.org/10.1096/fj.201901902RR.CrossRef

42.

Bustacchini S, Abbatecola AM, Bonfigli AR, Chiatti C, Corsonello A, Di Stefano G, et al. The Report-AGE project: a permanent epidemiological observatory to identify clinical and biological markers of health outcomes in elderly hospitalized patients in Italy. Aging Clin Exp Res. 2015;27:893–901. https://doi.org/10.1007/s40520-015-0350-3.CrossRef

Title: Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients
Authors: M. Cardelli
E. Pierpaoli
F. Marchegiani
F. Marcheselli
F. Piacenza
R. Giacconi
R. Recchioni
T. Casoli
P. Stripoli
M. Provinciali
G. Matacchione
A. Giuliani
D. Ramini
J. Sabbatinelli
M. Bonafè
M. Di Rosa
A. Cherubini
C. Di Pentima
F. Spannella
R. Antonicelli
A. R. Bonfigli
F. Olivieri
F. Lattanzio
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: SARS-CoV-2
COVID-19
Biomarkers
Published in: Immunity & Ageing / Issue 1/2022
Electronic ISSN: 1742-4933
DOI: https://doi.org/10.1186/s12979-022-00315-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Correction: The oldest unvaccinated Covid-19 survivors in South America

The accumulation of Vγ4 T cells with aging is associated with an increased adaptive Vγ4 T cell response after foodborne Listeria monocytogenes infection of mice

Telomerase deficiency reflects age-associated changes in CD4+ T cells

Age-associated phenotypic imbalance in TCD4 and TCD8 cell subsets: comparison between healthy aged, smokers, COPD patients and young adults

Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics

Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials